Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Поздний репродуктивный возраст и современные технологии
Поздний репродуктивный возраст и современные технологии
Поздний репродуктивный возраст и современные технологии. Гинекология. 2019; 21 (4): 27–31.
DOI: 10.26442/20795696.2019.4.190563
DOI: 10.26442/20795696.2019.4.190563
DOI: 10.26442/20795696.2019.4.190563
________________________________________________
DOI: 10.26442/20795696.2019.4.190563
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Инструкция по медицинскому применению лекарственного препарата Дюфастон® 10 мг, таблетки, покрытые пленочной оболочкой, 26.02.2018.
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Diufaston® 10 mg, tabletki, pokrytye plenochnoi obolochkoi, 26.02.2018 (in Russian).]
2. Инструкция по медицинскому применению лекарственного препарата Утрожестан® от 16.06.2017.
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Utrozhestan® ot 16.06.2017 (in Russian).]
3. Schindler AE. Maturitas 2009; 65: S3–S11.
4. Сайт grls.rosminzdrav.ru, доступ 20.08.2018.
[Sait grls.rosminzdrav.ru, dostup 20.08.2018 (in Russian).]
5. Rižner TL et al. Steroids 2011; 76 (6): 607–15.
6. Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C. Use of oral dydrogesterone for luteal phase support in fresh IVF cycles is associated with an increase in live birth rate: an integrated individual patient data analysis of the lotus phase iii trial program. Fertil Steril 2018; 110 (4): e90.
7. Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 2009; 65 (Suppl. 1): S47–S50.
8. Kumar A et al. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril 2014; 102 (5): 1357–63.e3.
9. Coomarasamy A et al. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. New Engl J Med 2019; 380: 1815–24. DOI: 10.1056/NEJMoa1813730
10. Coomarasamy A et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med 2015; 373 (22): 2141–8.
11. Тетруашвили Н.К., Агаджанова А.А. Дидрогестерон в лечении угрожающего и привычного выкидыша. Мед. совет. 2018; 3: 34–8.
[Tetruashvili N.K., Agadzhanova A.A. Didrogesteron v lechenii ugrozhaiushchego i privychnogo vykidysha. Med. sovet. 2018; 3: 34–8 (in Russian).]
12. Прохоренко Н.Ф. Демографический потенциал: дополнительные аспекты. ОРГЗДРАВ: новости, мнения, обучение. Вестн. ВШОУЗ. 2019; 5 (2): 22–47.
[Prokhorenko N.F. Demograficheskii potentsial: dopolnitel'nye aspekty. ORGZDRAV: novosti, mneniia, obuchenie. Vestn. VShOUZ. 2019; 5 (2): 22–47 (in Russian).]
2. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Utrozhestan® ot 16.06.2017 (in Russian).
3. Schindler AE. Maturitas 2009; 65: S3–S11.
4. Sait grls.rosminzdrav.ru, dostup 20.08.2018 (in Russian).
5. Rižner TL et al. Steroids 2011; 76 (6): 607–15.
6. Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C. Use of oral dydrogesterone for luteal phase support in fresh IVF cycles is associated with an increase in live birth rate: an integrated individual patient data analysis of the lotus phase iii trial program. Fertil Steril 2018; 110 (4): e90.
7. Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 2009; 65 (Suppl. 1): S47–S50.
8. Kumar A et al. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril 2014; 102 (5): 1357–63.e3.
9. Coomarasamy A et al. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. New Engl J Med 2019; 380: 1815–24. DOI: 10.1056/NEJMoa1813730
10. Coomarasamy A et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med 2015; 373 (22): 2141–8.
11. Tetruashvili N.K., Agadzhanova A.A. Didrogesteron v lechenii ugrozhaiushchego i privychnogo vykidysha. Med. sovet. 2018; 3: 34–8 (in Russian).
12. Prokhorenko N.F. Demograficheskii potentsial: dopolnitel'nye aspekty. ORGZDRAV: novosti, mneniia, obuchenie. Vestn. VShOUZ. 2019; 5 (2): 22–47 (in Russian).
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Diufaston® 10 mg, tabletki, pokrytye plenochnoi obolochkoi, 26.02.2018 (in Russian).]
2. Инструкция по медицинскому применению лекарственного препарата Утрожестан® от 16.06.2017.
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Utrozhestan® ot 16.06.2017 (in Russian).]
3. Schindler AE. Maturitas 2009; 65: S3–S11.
4. Сайт grls.rosminzdrav.ru, доступ 20.08.2018.
[Sait grls.rosminzdrav.ru, dostup 20.08.2018 (in Russian).]
5. Rižner TL et al. Steroids 2011; 76 (6): 607–15.
6. Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C. Use of oral dydrogesterone for luteal phase support in fresh IVF cycles is associated with an increase in live birth rate: an integrated individual patient data analysis of the lotus phase iii trial program. Fertil Steril 2018; 110 (4): e90.
7. Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 2009; 65 (Suppl. 1): S47–S50.
8. Kumar A et al. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril 2014; 102 (5): 1357–63.e3.
9. Coomarasamy A et al. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. New Engl J Med 2019; 380: 1815–24. DOI: 10.1056/NEJMoa1813730
10. Coomarasamy A et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med 2015; 373 (22): 2141–8.
11. Тетруашвили Н.К., Агаджанова А.А. Дидрогестерон в лечении угрожающего и привычного выкидыша. Мед. совет. 2018; 3: 34–8.
[Tetruashvili N.K., Agadzhanova A.A. Didrogesteron v lechenii ugrozhaiushchego i privychnogo vykidysha. Med. sovet. 2018; 3: 34–8 (in Russian).]
12. Прохоренко Н.Ф. Демографический потенциал: дополнительные аспекты. ОРГЗДРАВ: новости, мнения, обучение. Вестн. ВШОУЗ. 2019; 5 (2): 22–47.
[Prokhorenko N.F. Demograficheskii potentsial: dopolnitel'nye aspekty. ORGZDRAV: novosti, mneniia, obuchenie. Vestn. VShOUZ. 2019; 5 (2): 22–47 (in Russian).]
________________________________________________
2. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Utrozhestan® ot 16.06.2017 (in Russian).
3. Schindler AE. Maturitas 2009; 65: S3–S11.
4. Sait grls.rosminzdrav.ru, dostup 20.08.2018 (in Russian).
5. Rižner TL et al. Steroids 2011; 76 (6): 607–15.
6. Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C. Use of oral dydrogesterone for luteal phase support in fresh IVF cycles is associated with an increase in live birth rate: an integrated individual patient data analysis of the lotus phase iii trial program. Fertil Steril 2018; 110 (4): e90.
7. Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 2009; 65 (Suppl. 1): S47–S50.
8. Kumar A et al. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril 2014; 102 (5): 1357–63.e3.
9. Coomarasamy A et al. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. New Engl J Med 2019; 380: 1815–24. DOI: 10.1056/NEJMoa1813730
10. Coomarasamy A et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med 2015; 373 (22): 2141–8.
11. Tetruashvili N.K., Agadzhanova A.A. Didrogesteron v lechenii ugrozhaiushchego i privychnogo vykidysha. Med. sovet. 2018; 3: 34–8 (in Russian).
12. Prokhorenko N.F. Demograficheskii potentsial: dopolnitel'nye aspekty. ORGZDRAV: novosti, mneniia, obuchenie. Vestn. VShOUZ. 2019; 5 (2): 22–47 (in Russian).
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.